SCHEMBL18171997

SCHEMBL18171997

Cc1cccc(NN=C(c2ccccc2)c2ccccc2)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
HTT P42858 3/20 0.46
LMNA P02545 1/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
MAPT P10636 3/20 0.45
GAA P10253 3/20 0.45
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HPGD P15428 2/20 0.40
POLB P06746 1/20 0.40
CTSL P07711 2/20 0.39
CTSB P07858 2/20 0.39
ALOX12 P18054 1/20 0.38
KDM4C Q9H3R0 1/20 0.37
RAB9A P51151 2/20 0.36
PTBP1 P26599 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3897223 0.84 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL12757681 0.75 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL27254536 0.75 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL10021267 0.73 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL31648930 0.72 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL20265071 0.72 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL6267441 0.71 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL29496057 0.71 CYP3A4 (0.53) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL1011078 0.71 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL18133119 0.70 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HTTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105509-A1 AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS ALMIRALL, S.A. (ES) 2018-04-19 US disclosed
EP-3286178-A1 AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS Almirall S.A. (ES) 2018-02-28 EP disclosed
WO-2016170009-A1 AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS ALMIRALL, S.A. (ES) 2016-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180105509-A1 AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS SCN7A, SCN1A, SCN1B ALDH1A1 1764/4885SMN1; SMN2 568/4885HTT 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.